Genmab stock rallies after Epkinly shows strong results in 2L lymphoma trial

Investing.com Gold reports: Genmab stock rallies after Epkinly shows strong results in 2L lymphoma trial. Full body text was unavailable at ingest time, so this brief is based on headline context.